Patrick Temple-West and Stefania PalmaAug 20, 2026 – 8.33amNew York/London | Shares in US vaccine-maker Moderna nearly tripled after it reported successful trial results for an experimental skin cancer therapy.The experimental therapy, jointly developed with Merck, would be unprecedented in cancer treatment, providing a custom-made vaccine for each patient depending on their specific tumours. Analysts expect US regulatory approval next year.Financial TimesSubscribe to gift this articleGift 5 articles to anyone you choose each month when you subscribe.Subscribe nowAlready a subscriber? Fetching latest articles
Moderna shares nearly triple on skin cancer vaccine success
The experimental therapy, jointly developed with Merck, would be unprecedented in cancer treatment, providing a custom-made vaccine for each patient.
83 words~1 min read
